mirago-prescribing-guide

Complete bedside prescribing reference for Mirago (mirabegron, beta-3 adrenoceptor agonist) for overactive bladder — covering contraindications, safety screening, drug interactions, dose selection in

SKILL.md

GitHub

Mirago (mirabegron) — Complete Prescribing Guide

Indian brand: Mirago | Drug class: Selective beta-3 adrenoceptor agonist
Available strengths: 25 mg, 50 mg extended-release tablets (once daily)


STEP 1 — Confirm Indication

Indicated for: Overactive bladder (OAB) in adults with:

  • Urgency
  • Urgency urinary incontinence
  • Urinary frequency

Not established in: Pediatrics (<18 years)
Geriatrics (≥65 years): Safe to use — no dose adjustment needed


STEP 2 — Contraindications (Hard Stop)

Do NOT prescribe if ANY of these apply:

Condition Threshold
Severe uncontrolled hypertension SBP ≥180 mmHg and/or DBP ≥110 mmHg
Pregnancy Any trimester
Hypersensitivity to mirabegron Any ingredient in the formulation

STEP 3 — Safety Warnings (Proceed with Caution)

Work through each before prescribing:

Cardiovascular

  • Hypertension (controlled): Check BP at baseline and periodically. Mirago raises BP ~0.5–1 mmHg in OAB patients; up to 4/3.7 mmHg in healthy volunteers at 50 mg.
  • QTc prolongation risk: Mirago causes dose-dependent QTc prolongation (<5 ms at 50 mg — therapeutic dose). Use with caution if: known QT prolongation history, hypokalemia, or concurrent QTc-prolonging drugs.
  • Tachyarrhythmia / ischemic heart disease: Mirago increases HR by ~1 bpm (OAB patients at 50 mg); up to 8.5 bpm in healthy female volunteers. Use caution.

Genitourinary

  • Bladder outlet obstruction (BOO): Urinary retention reported post-marketing, especially with concurrent antimuscarinics. Use with caution.

Immune

  • Angioedema (face, lips, tongue, larynx): Rare but life-threatening. Discontinue immediately; secure airway if upper airway involved.

Ophthalmological

  • Glaucoma: Monitor IOP regularly during treatment (though 100 mg did not increase IOP in phase 1 studies).

Nursing mothers: Avoid — excreted in rodent milk; no human data.


STEP 4 — Drug Interaction Check

Run through this table for every patient:

Co-medication Mechanism Action Required
Flecainide, propafenone (narrow TI CYP2D6 substrates) Mirago ↑ their exposure substantially Cap Mirago at 25 mg/day. Do not escalate.
Metoprolol, desipramine (CYP2D6 substrates, wider TI) Mirago ↑ Cmax by ~79–90% Caution; monitor for β-blocker/TCA side effects
Digoxin Mirago weak P-gp inhibitor: ↑ digoxin Cmax 29%, AUC 27% Start digoxin at lowest dose; titrate by serum levels
Antimuscarinics for OAB (solifenacin, oxybutynin, etc.) Additive urinary retention risk in BOO Caution in BOO; watch for retention
QTc-prolonging drugs (see list below) Additive QTc risk Avoid combination if patient has QT risk factors
Warfarin Minor ↑ in warfarin Cmax/AUC (~4–9%); no INR effect on single dose Monitor INR; long-term interaction not fully studied
Metformin, solifenacin, tamsulosin, ketoconazole, rifampicin No clinically significant PK interaction No dose adjustment needed

QTc-prolonging drugs to flag: Class IA/IC/III antiarrhythmics · Antipsychotics (haloperidol, chlorpromazine, ziprasidone) · TCAs (amitriptyline, imipramine) · Macrolides (erythromycin, clarithromycin) · Quinolones (moxifloxacin, levofloxacin) · Azole antifungals · Antimalarials (chloroquine, quinine) · Methadone · Domperidone · 5-HT3 antagonists (ondansetron) · SSRIs/SNRIs (fluoxetine, citalopram, venlafaxine)


STEP 5 — Dose Selection by Patient Profile

Patient Starting Dose Maximum Dose
Standard adult 25 mg OD 50 mg OD
Elderly ≥65 years 25 mg OD 50 mg OD (no adjustment)
Mild renal impairment (CrCl/eGFR 30–89 mL/min) 25 mg OD 50 mg OD
Severe renal impairment (CrCl/eGFR 15–29 mL/min) 25 mg OD 25 mg OD — do not escalate
ESRD (CrCl/eGFR <15, or on dialysis) NOT RECOMMENDED —
Mild hepatic impairment (Child-Pugh A) 25 mg OD 50 mg OD
Moderate hepatic impairment (Child-Pugh B) 25 mg OD 25 mg OD — do not escalate
Severe hepatic impairment (Child-Pugh C) NOT RECOMMENDED —
With flecainide or propafenone 25 mg OD 25 mg OD — do not escalate

STEP 6 — Titration and Administration

  • Start: 25 mg once daily, with or without food
  • Assess response: At 8 weeks (effective within 8 weeks at 25 mg)
  • Escalate to 50 mg: If inadequate response and well-tolerated; once daily
  • Do not exceed 50 mg/day (supra-proportional bioavailability increases above this dose)
  • Administration: Swallow whole with water — do NOT crush, chew, or divide tablet
  • Missed dose: Take next scheduled dose as usual — never double-dose

STEP 7 — Clinical Guardrails

  • Urine dipstick protein: Mirago may cause false-positive results. Always confirm with quantitative protein assay if dipstick is positive.
  • Liver enzymes: ALT/AST rose >10-fold in 0.3% of patients on 50 mg in long-term studies (subsequently normalised). Monitor if hepatic symptoms develop.
  • Angioedema: Can occur after first dose or after multiple doses. If tongue, hypopharynx, or larynx involved — STOP immediately, manage airway.
  • Stevens-Johnson syndrome: Rare (single case report at 100 mg). Discontinue if severe skin reaction develops.
  • Do not use in pregnancy — embryo-fetal toxicity in animals (wavy rib, cardiomegaly, reduced fetal weight).
  • Neoplasm signal: 1.3% at 100 mg (long-term study) vs 0.1% at 50 mg and 0.5% active control — unclear significance; not a reason to avoid at therapeutic dose (50 mg), but worth noting in long-term users.

Source: Myrbetriq (mirabegron) Canadian Product Monograph, Astellas Pharma Canada, June 2016. Submission No: 192447. Indian brand equivalent: Mirago (mirabegron).